a new differentiated and promising approach to treating brain cancer

Webinar on Tuesday, November 23 at 2:00 p.m. CET (8:00 a.m. EST)

BERLIN, November 16, 2021– (BUSINESS WIRE) – Regulatory news:

NOXXON Pharma NV (Euronext Growth Paris: ALNOX) (Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), today announced that its thought leader webinar (KOL) on NOX-A12 and the combination radiotherapy, which is a promising new approach to treating brain cancer, will be hosted on Tuesday, November 23, 2021 at 2:00 p.m. CET (8:00 a.m. EST).

The webinar will include a presentation by Frank A. Giordano, MD, Director and Chairman of the Department of Radiation Oncology, University Hospital Bonn, Germany, who will discuss the current therapeutic landscape and the high unmet medical needs in the treatment of patients with brain cancer, in particular glioblastoma multiforme, GBM. Following his presentation at the Society for Neuro-Oncology (SNO) annual meeting on November 19, Dr. Giordano will discuss in more detail the latest promising results from the GLORIA study, evaluating NOX-A12 in combination with radiation therapy in patients with first-line brain cancer. with the unmethylated MGMT promoter.

The NOXXON leadership team will also provide an overview of the company and an update on clinical programs. Dr Giordano will be available for questions after the official presentation.

To register for the event, please click here.

NOX-A12 is an inhibitor of the chemokine CXCL12 and has been granted orphan drug status in the US and EU for the treatment of certain brain cancers and has so far produced encouraging clinical data. Dr Giordano will also compare data from the NOXXON trial to historical data assessing how a matched cohort of patients responded to treatment according to the current standard of care, which has remained unchanged since 2006.

Frank Giordano, MD, is Director and Chairman of the Department of Radiation Oncology at University Hospital Bonn, Germany. He is an expert in precision radiotherapy and intraoperative irradiation of malignant tumors and has received international recognition for his research on brain tumors, including an award from the American Society of Radiation Oncology (ASTRO) and an honorary member of the Society. Spanish Radiation Oncology (SEOR). Dr Giordano received his medical degree from the University of Heidelberg, Germany, and completed his postgraduate training as a Peter Engelhorn Fellow at the German Cancer Research Center (DKFZ). He received clinical training at the National Center for Tumor Diseases (NCT) Heidelberg and the University Medical Center Mannheim, where he served as Acting Chairman and Head of the Radiation Oncology Department before moving to Bonn. For many years, his research has focused on optimized radiotherapy of brain cancers to offer cancer patients a personalized and even more effective treatment. As one of the few Else-Kröner-Fresenius Excellence Fellows, Dr Giordano has developed innovative treatment options that have even found their way into clinical practice. He sees great potential in the combination of radiotherapy and immunomodulatory therapy.


NOXXON’s oncology-focused pipeline acts on the tumor microenvironment (TME) and the cancer immunity cycle by breaking down the tumor protective barrier and blocking tumor repair. By neutralizing the chemokines in TME, NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and allow greater therapeutic impact. NOXXON’s main program, NOX-A12, provided the final revenue data of a Keytruda® combined trial in patients with metastatic colorectal and pancreatic cancer published at the ESMO conference in September 2020 and July 2021, the company announced its phase 2 study, OPTIMUS, to further assess safety and efficacy NOX-A12 in combination with Keytruda from Merck® and two different chemotherapy regimens as second-line treatment in patients with metastatic pancreatic cancer. NOXXON is also studying NOX-A12 in brain cancer in combination with radiation therapy, which has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. GLORIA, a trial of NOX-A12 in combination with radiation therapy in patients with newly diagnosed brain cancer who will not clinically benefit from standard chemotherapy, provided interim data from the first two cohorts showing consistent tumor reductions and objective tumor responses. The company’s second clinical-stage active, NOX-E36, is a phase 2 TME active targeting the innate immune system. NOXXON plans to test NOX-E36 in patients with solid tumors. More information is available at: www.noxxon.com.

Keytruda® is a registered trademark of Merck Sharp & Dohme Corp.

Visit NOXXON on LinkedIn and Twitter.

About the GLORIA study

GLORIA (NCT04121455) is the phase 1/2 dose escalation study of NOXXON of NOX-A12 in combination with irradiation in patients with first-line glioblastoma (brain cancer) with a non-MGMT promoter. methylated (resistant to standard chemotherapy).

About the OPTIMUS study

OPTIMUS (NCT04901741) is NOXXON’s open-label, two-arm phase 2 study of NOX-A12 in combination with pembrolizumab and nanoliposomal irinotecan / 5-FU / leucovorin or gemcitabine / nab-paclitaxel in patients with ‘stable microsatellite metastatic pancreatic cancer.


Certain statements in this communication contain wording or terms that refer to future or future developments, as well as negations of such wordings or terms, or similar terminology. These are described as forward-looking statements. In addition, all information contained in this communication concerning the expected or future results of the business segments, financial indicators, changes in the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions potential investors not to rely on these forward-looking statements as certain predictions of actual future events and developments. The company is neither responsible nor liable for updating this information, which only represents the inventory on the day of publication.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20211115005826/en/


Aram Mangasarian, Ph.D.
Chief Executive Officer
Phone. +49 (0) 30 726247 0
[email protected]

Investor and media relations:

LifeSci Advisors
Guillaume de Renterghem
Phone. +41 (0) 76 735 01 31
[email protected]

Arthur Rusty
Phone. +33 (0) 1 44 71 00 15
[email protected]

Source link

About Geraldine Higgins

Check Also

Delaware Investments® Dividend and Income Fund, Inc. Announces Distributions

PHILADELPHIA CREAM–(BUSINESS WIRE)–Today, Delaware Investments Dividend and Income Fund, Inc. (the “Fund”), a closed-end fund …